23andMe raises more than US$80m in Series F round
[NEW YORK] DNA testing company 23andMe raised more than US$80 million in equity in a financing round led by Sequoia Capital and NewView Capital.
According to Securities and Exchanges Commission filings, the company offered US$85 million in equity and sold about US$82.5 million. Previously, the company had raised about US$791 million. The Series F financing will be used for general corporate purposes, spokesperson Andy Kill said.
Consumer genetics firms like 23andMe have helped to turn recreational DNA testing into a widespread phenomenon, as more than 12 million of its customers have spit into a tube to learn about their ancestry and health background. The company cut 14 per cent of its jobs earlier this year as sales of its services slowed.
In recent years, 23andMe has begun moving beyond telling individual consumers about their DNA and begun work developing therapeutics based on research into genetic information its customers provide. For example, the company has used its data to find genetic differences that can affect a person's susceptibility to Covid-19.
BLOOMBERG
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Startups
Grab-led GXBank teams up with Zurich to offer affordable insurance
GoTo eyes private placement of 120.1 billion shares
SoftBank leads US$1 billion funding for UK self-driving startup Wayve
Singapore battles to revive struggling stock market
NSG BioLabs bags US$14.5 million funding; inks tie-ups with Merck, EnterpriseSG
Singapore’s Anywheel gets green light to expand fleet to 35,000